What strength of estradiol valerate (Delestrogen) should I order for a patient transitioning from oral micronized estradiol 2 mg twice daily?

Estradiol Valerate (Delestrogen) Dosing Recommendation

For a patient transitioning from oral micronized estradiol 2 mg twice daily (4 mg total daily), start with Delestrogen 10 mg intramuscularly every 2 weeks or 5 mg weekly, using the 10 mg/mL or 20 mg/mL concentration vial.

Rationale for This Dosing

The current guidelines suggesting 2-20 mg weekly or 5-30 mg every 2 weeks are too high and consistently produce supraphysiologic estradiol levels 1. Recent high-quality evidence demonstrates that:

• 78.3% of patients on 3 mg weekly and 76.0% on 4 mg weekly achieved physiologic estradiol concentrations (100-357 pg/mL) 2
• Most patients who fell outside the Endocrine Society's recommended 100-200 pg/mL range were above this range, not below 2
• Injectable estradiol monotherapy effectively suppresses testosterone to <50 ng/dL in 82.6% of patients without requiring antiandrogens 3

Specific Dosing Algorithm

Starting Dose Selection:

• First-line: 10 mg intramuscularly every 2 weeks (equivalent to ~5 mg weekly)
• Alternative: 5 mg intramuscularly or subcutaneously weekly

Vial Concentration Choice:

The FDA label indicates Delestrogen is available in three concentrations 4:

• 10 mg/mL (in chlorobutanol and sesame oil)
• 20 mg/mL (in benzyl benzoate, benzyl alcohol, and castor oil)
• 40 mg/mL (in benzyl benzoate, benzyl alcohol, and castor oil)

Order the 10 mg/mL or 20 mg/mL concentration. The 40 mg/mL concentration is unnecessarily high for typical dosing and the FDA label specifically notes it "provides a high concentration in a small volume" requiring "particular care" 4, making it less practical for starting doses.

Monitoring and Titration

• Check estradiol levels mid-cycle (3-4 days after injection for weekly dosing, or 7 days after injection for every-2-week dosing)
• Target estradiol: 100-200 pg/mL per Endocrine Society guidelines 5
• Check testosterone levels simultaneously; target <55 ng/dL 5
• Do not increase dose reflexively if levels are 200-357 pg/mL, as this still represents physiologic female range 2

Critical Pitfalls to Avoid

Common dosing errors:

• Starting at doses ≥10 mg weekly leads to supraphysiologic levels in most patients 1, 2
• The traditional FDA-approved dosing of 10-20 mg every 4 weeks 4 is inadequate for gender-affirming therapy and produces wide fluctuations
• Checking levels at trough (just before next injection) underestimates average exposure

Route considerations:

• Both intramuscular and subcutaneous routes are effective with no significant difference in testosterone suppression 3
• Subcutaneous may be preferred by some patients for ease of self-administration
• Use 20-gauge × 1.5-inch needle for IM injection into upper outer quadrant of gluteal muscle 4

Antiandrogen Considerations

Injectable estradiol monotherapy is highly effective and antiandrogens may not be necessary 3. However, if testosterone remains >50 ng/dL after 3 months on adequate estradiol dosing:

• Consider adding spironolactone (though it showed no significant independent effect on testosterone in recent data 3)
• Progestogen use was independently associated with lower testosterone and may be more effective than spironolactone 3

Important Safety Context

While the provided guidelines focus on premature ovarian insufficiency and menopause [6-6], the principles of using lower estradiol doses and avoiding supraphysiologic levels apply universally to minimize cardiovascular, thromboembolic, and hepatic risks. The transdermal route (50-100 μg daily patches) recommended in those guidelines [6-6] avoids first-pass hepatic metabolism, but injectable estradiol at appropriate doses can achieve similar physiologic levels with better compliance for many patients.

The evidence strongly supports starting low (≤5 mg weekly equivalent) and titrating based on measured levels rather than using traditional higher starting doses.